Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases

Abstract

Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.

1 . A compound of formula (I) 
       
         
           
           
               
               
           
         
         in which 
         R 1  is hydrogen, halogen, 1-3C-alkyl, 
         R 2 /R 3  are independently from each other hydrogen, halogen, cyano, hydroxy 1-6C-haloalkyl, 1-6C-haloalkoxy, 1-6C-alkoxy, 
         R 4  is independently hydrogen, hydroxy, halogen, cyano, NO 2 , 1-6C-alkyl, 2-6C-alkenyl, 2-6C-alkynyl, 1-6C-haloalkyl, 1-6C-hydroxyalkyl, 1-6C-alkoxy, —O-(2-6C-alkylen)-O—C(O)-(1-6C-alkyl), 1-6C-haloalkoxy, —C(O)OR 9 , -(1-6C-alkylen)-C(O)OR 9 , —C(O)-(1-6C-alkyl), —C(O)NR 10 R 11 , 3-7C-cycloalkyl, —S-(1-6C-haloalkyl), SF 5 , —SO 2 NH-(3-7C-cycloalkyl), —SO 2 NR 10 R 11 , NR 10 R 11 ,
 heteroaryl which optionally is substituted independently one or more times with cyano, 1-4C-alkyl, 1-6C-haloalkyl, 1-6C-haloalkoxy, C(O)OR 9 , C(O)NR 10 R 11 , whereby two of R 2 , R 3  (R 4 ) n , when positioned ortho to each other, may form together with the two carbon atoms to which they are attached, a heterocyclic 5-, 6- or 7-membered ring containing 1 or 2 heteroatoms selected from O or N, and optionally containing an additional double bond and/or optionally substituted by an oxo (═O) group and/or an 1-4C-alkyl group, 
 
         n 0-3 
         R 6  is (a) hydrogen;
 (b) hydroxy; 
 (c) cyano; 
 (d)1-6C-alkoxy optionally substituted independently one or more times with
 (d1) OH, 
 (d2) —O-(1-6C-alkyl) 
 (d3) C(O)OR 9 , 
 (d4) C(O)NR 10 R 11 , 
 (d5) NR 10 R 11 , 
 (d6) —S-(1-6C-alkyl), 
 (d7) —S(O)-(1-6C-alkyl), 
 (d8) —SO 2 -(1-6C-alkyl) 
 (d9) SO 2 NR 10 R 11 , 
 (d10) heterocyclyl, which is optionally substituted with C(O)OR 9 , or oxo (═O), 
 (d11) heteroaryl, which is optionally substituted independently one or more times with cyano, 1-4C-alkyl, 1-6C-haloalkyl, 1-6C-haloalkoxy, C(O)OR 9 , C(O)NR 10 R 11 , (1-6C-alkylen)-O-(1-6C-alkyl), 
 
 (e) SO 2 NR 10 R 11 , 
 (f)3-7C-cycloalkoxy, 
 (g)1-6C-haloalkoxy, 
 (h) COOR 9 , 
 (i) —C(O)NR 10 R 11 , 
 (j) —O-heteroaryl opt. subst. with CN 
 
       
       
         
           
           
               
               
           
         
       
       whereby the * is the point of attachment,
   (l) —O-(2-6C-alkylen)-O-(1-6C-alkyl) which is optionally substituted with hydroxy, NH(CO)OR 9 ,   
 R 7  is
 (a) hydrogen, 
 (b) 1-6C-alkyl, which is optionally substituted with heteroaryl 
 (c) 1-6C-haloalkyl, 
 (d) 1-6C-hydroxyalkyl, 
 
 
       
         
           
           
               
               
           
         
       
       whereby the * is the point of attachment,
   (f) —C(O)-(1-6C-alkyl),   (g) —C(O)-(1-6C-alkylen)-O-(1-6C-alkyl),   (h) —C(O)-(1-6C-alkylen)-O-(2-6C-alkylen)-O-(1-6C-alkyl),   (i) —C(O)-heterocyclyl,   (j) benzyl whereby the phenyl ring is opt. subst with 1-5 substituents independently selected from the group consisting of hydrogen, halogen, 1-4C-alkyl, 1-4C-haloalkyl, 1-4C-alkoxy, 1-4C-haloalkoxy, cyano, C(O)OR 9 ,   (k) heteroaryl   or   optionally, R 6  and R 7  together with the nitrogen atom to which R 7  is attached form a 6-membered ring which may contain one further heteroatom selected from the group consisting of O, S, N,
 and which is optionally substituted by (1-6C-alkyl)-OH, (1-6C-alkyl)-NR 10 R 11 , 
   
 R 8  is hydrogen, halogen, hydroxy, cyano, 1-6C-alkyl, 1-6C-hydroxyalkyl, 1-6C-haloalkyl, 1-6C-haloalkoxy, C(O)OR 9 , C(O)NR 10 R 11 , 
 m is 0-4 
 R 9  is (a) hydrogen,
 (b) 1-6C-alkyl which optionally is substituted with hydroxy, 
 
 R 10 R 11  are independently from each other hydrogen, 1-4C-alkyl, 1-4C-hydroxyalkyl, 1-4C-alkoxy, —(CO)-(1-6C-alkyl), CHO, COOR 9 , or
 together with the nitrogen atom to which they are attached form a 4-6-membered heterocyclic ring optionally containing one further heteroatom selected from the group consisting of O, S or N, and which is optionally substituted with 1-2 fluorine atoms or COOR 9 , 
 
 or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer. 
 
     
     
         2 . The compound of formula (I) according to  claim 1 ,
 wherein   R 1  is hydrogen, halogen, 1-3C-alkyl,   R 2 /R 3  are independently from each other hydrogen, halogen, cyano, 1-6C-haloalkyl, 1-6C-haloalkoxy,   R 4  is independently hydrogen, halogen, cyano, 1-6C-alkyl, 2-6C-alkenyl, 1-6C-haloalkyl, 1-6C-hydroxyalkyl, 1-6C-alkoxy, 1-6C-haloalkoxy, —C(O)OR 9 , -(1-6C-alkylen)-C(O)OR 9 , —C(O)-(1-6C-alkyl), —C(O)NR 10 R 11 , 3-7C-cycloalkyl, —S-(1-6C-haloalkyl), SF 5 , —SO 2 NH-(3-7-cycloalkyl), —SO 2 NR 10 R 11 ,
 heteroaryl which optionally is substituted independently one or more times with cyano, 1-4C-alkyl, 1-6C-haloalkyl, 1-6C-haloalkoxy, C(O)OR 9 , C(O)NR 10 R 11 , whereby two of R 2 , R 3  (R 4 ) n , when positioned ortho to each other, may form together with the two carbon atoms to which they are attached, a heterocyclic 5-, 6- or 7-membered ring containing 1 or 2 heteroatoms selected from O or N, and optionally an additional double bond and/or a carbonyl group and/or an 1-4C-alkyl group, 
   n 0-3   R 6  is (a) hydrogen;
 (b) hydroxy; 
 (c) cyano; 
 (d) 1-6C-alkoxy opt. subst. with
 (d1) 1-2 OH, 
 
 (d2) NR 10 R 11 , 
 (d3) SO 2 NR 10 R 11 , 
 (d4) heterocyclyl, 
 (d5) heteroaryl, which is optionally substituted independently one or more times with cyano, 1-4Calkyl, 1-6C-haloalkyl, 1-6C-haloalkoxy, C(O)OR 9 , C(O)NR 10 R 11 , 
 (e) SO 2 NR 10 R 11 , 
 (f) 3-7C-cycloalkoxy, 
 (g) 1-6C-haloalkoxy, 
 (h) —C(O)NR 10 R 11 , 
 (i) —O-heteroaryl opt. subst. with CN 
   
       
         
           
           
               
               
           
         
       
       whereby the * is the point of attachment,
 R 7  is
 (a) hydrogen, 
 (b) 1-6C-alkyl, which is optionally substituted with heteroaryl 
 (c) 1-6C-haloalkyl, 
 (d) 1-6C-hydroxyalkyl, 
 
 
       
         
           
           
               
               
           
         
       
       whereby the * is the point of attachment,
   (f) —C(O)-(1-6C-alkyl)   (g) —C(O)-(1-6C-alkylen)-O-(1-6C-alkyl)   (h) —C(O)-(1-6C-alkylen)-O-(1-6C-alkylen)-O-(1-6C-alkyl)   (i) —C(O)-heterocyclyl,   (j) benzyl whereby the phenyl ring is opt. subst with 1-5 substituents independently selected from the group consisting of
 hydrogen, halogen, 1-4Calkyl, 1-4C-haloalkyl, 1-4C-alkoxy, 1-4C-haloalkoxy, cyano, 
 C(O)OR 9 , 
   (k) heteroaryl   or   optionally R 6  and R 7  together with the nitrogen atom to which they are attached form a 6-membered ring which may contain one further heteroatom selected from the group consisting of O, S, N,
 and which is optionally substituted by hydroxy-(1-6alkyl), 
   
 R 8  is hydrogen, halogen, cyano, 1-6C-haloalkyl, 1-6C-haloalkoxy, C(O)OR 9 , C(O)NR 10 R 11 , 
 m is 0-4 
 R 9  is (a) hydrogen,
 (b) 1-6C-alkyl which optionally may be substituted with hydroxy, 
 
 R 10 , R 11  are independently from each other hydrogen, 1-4C-alkyl, 1-4C-hydroxyalkyl, 1-4C-alkoxy, or
 together with the nitrogen atom to which they are attached form a 5-6-membered heterocyclic ring optionally containing one further heteroatom selected from the group consisting of O, S or N, 
 
 or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer. 
 
     
     
         3 . The compound of formula (I) according to  claim 1 ,
 wherein   R 1  is hydrogen, halogen, 1-3C-alkyl,   R 2 /R 3  are independently from each other hydrogen, halogen, cyano, hydroxy, 1-3C-haloalkyl, 1-3C-haloalkoxy, 1-3C-alkoxy,   R 4  is independently hydrogen, hydroxy, halogen, cyano, NO 2 , 1-3C-alkyl, 2-3C-alkenyl, 2-3C-alkynyl, 1-3C-haloalkyl, 1-3C-hydroxyalkyl, 1-3C-alkoxy, —O-(2-3C-alkylen)-O—C(O)-(1-3C-alkyl), 1-3C-haloalkoxy, —C(O)OR 9 , -(1-3C-alkylen)-C(O)OR 9 , —C(O)-(1-3C-alkyl), —C(O)NR 10 R 11 , 3-7C-cycloalkyl, —S-(1-3C-haloalkyl), SF 5 , —SO 2 NH-(3-7C-cycloalkyl), —SO 2 NR 10 R 11 , NR 10 R 11 ,
 heteroaryl which optionally is substituted independently one or more times with cyano, 1-3C-alkyl, 1-3C-haloalkyl, 1-3C-haloalkoxy, C(O)OR 9 , C(O)NR 10 R 11 , whereby two of R 2 , R 3  (R 4 ) n , when positioned ortho to each other, may form together with the two carbon atoms to which they are attached, a heterocyclic 5-, 6- or 7-membered ring containing 1 or 2 heteroatoms selected from O or N, and optionally containing an additional double bond and/or optionally substituted by an oxo (═O) group and/or an 1-3C-alkyl group, 
   n 0-3   R 6  is (a) hydrogen;
 (b) hydroxy; 
 (c) cyano; 
 (d) 1-6C-alkoxy optionally substituted independently one or more times with
 (d1) OH, 
 (d2) —O-(1-3C-alkyl) 
 (d3) C(O)OR 9 , 
 (d4) C(O)NR 10 R 11 , 
 (d5) NR 10 R 11 , 
 (d6) —S-(1-3C-alkyl), 
 (d7) —S(O)-(1-3C-alkyl), 
 (d8) —SO 2 -(1-3C-alkyl), 
 (d9) SO 2 NR 10 R 11 , 
 (d10) heterocyclyl, which is optionally substituted with C(O)OR 9 , or oxo (═O), 
 (d11) heteroaryl, which is optionally substituted independently one or more times with cyano, 1-3C-alkyl, 1-3C-haloalkyl, 1-3C-haloalkoxy, C(O)OR 9 , C(O)NR 10 R 11 , (1-3C-alkylen)-O-(1-3C-alkyl), 
 
 (e) SO 2 NR 10 R 11 , 
 (f) 3-7C-cycloalkoxy, 
 (g) 1-6C-haloalkoxy, 
 (h) COOR 9 , 
 (i) —C(O)NR 10 R 11 , 
 (j) —O-heteroaryl opt. subst. with CN 
   
       
         
           
           
               
               
           
         
       
       whereby the * is the point of attachment,
   (l) —O-(2-3C-alkylen)-O-(1-3C-alkyl) which is optionally substituted with hydroxy, NH(CO)OR 9 ,   
 R 7  is
 (a) hydrogen, 
 (b) 1-3C-alkyl, which is optionally substituted with heteroaryl 
 (c) 1-3C-haloalkyl, 
 (d) 1-3C-hydroxyalkyl, 
 
 
       
         
           
           
               
               
           
         
       
       whereby the * is the point of attachment,
   (f) —C(O)-(1-3C-alkyl)   (g) —C(O)-(1-3C-alkylen)-O-(1-3C-alkyl)   (h) —C(O)-(1-3C-alkylen)-O-(2-3C-alkylen)-O-(1-3C-alkyl)   (i) —C(O)-heterocyclyl,   (j) benzyl whereby the phenyl ring is opt. subst with 1-5 substituents independently selected from the group consisting of
 hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-haloalkoxy, cyano, 
 C(O)OR 9 , 
   (k) heteroaryl   or   optionally, R 6  and R 7  together with the nitrogen atom to which R 7  is attached form a 6-membered ring which may contain one further heteroatom selected from the group consisting of O, S, N,
 and which is optionally substituted by (1-3C-alkyl)-OH, 
 (1-3C-alkyl)-NR 10 R 11 , 
   
 R 8  is hydrogen, halogen, hydroxy, cyano, 1-3C-alkyl, 1-3C-hydroxyalkyl, 1-3C-haloalkyl, 1-3C-haloalkoxy, C(O)OR 9 , C(O)NR 10 R 11 , 
 m is 0-4 
 R 9  is (a) hydrogen,
 (b) 1-3C-alkyl which optionally is substituted with hydroxy, 
 
 R 10 , R 11  are independently from each other hydrogen, 1-3C-alkyl, 1-3C-hydroxyalkyl, 1-3C-alkoxy, —(CO)-(1-3C-alkyl), CHO, COOR 9  or
 together with the nitrogen atom to which they are attached form a 4-6-membered heterocyclic ring optionally containing one further heteroatom selected from the group consisting of O, S or N, which is optionally substituted with 1-2 fluorine atoms or COOR 9 , 
 
 or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer. 
 
     
     
         4 . The compound of formula (I) according to  claim 1 ,
 in which   R 1  is hydrogen, 1-3C-alkyl,   R 2 /R 3  are independently from each other hydrogen, halogen, cyano, hydroxy, 1-4C-haloalkyl, 1-4C-alkoxy,   R 4  is independently hydrogen, hydroxy, halogen, cyano, 1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, 1-4C-haloalkyl, 1-4C-hydroxyalkyl, 1-4C-alkoxy, —O-(2-4C-alkylen)-O—C(O)-(1-4C-alkyl), 1-4C-haloalkoxy, —C(O)OR 9 , -(1-4C-alkylen)-C(O)OR 9 , —C(O)-(1-4C-alkyl), —C(O)NR 10 R 11 , 3-7C-cycloalkyl, —S-(1-4C-haloalkyl), SF 5 , —SO 2 NH-(3-7C-cycloalkyl), —SO 2 NR 10 R 11 , NR 10 R 11 ,
 heteroaryl which optionally is substituted independently one or more times with cyano, 1-4C-alkyl, 1-4C-haloalkyl, 1-4C-haloalkoxy, C(O)OR 9 , C(O)NR 10 R 11 , whereby two of R 2 , R 3  (R 4 ) n , when positioned ortho to each other, may form together with the two carbon atoms to which they are attached, a heterocyclic 5-, 6- or 7-membered ring containing 1 or 2 heteroatoms selected from O or N, and optionally containing an additional double bond and/or optionally substituted by an oxo (═O) group and/or an 1-4C-alkyl group, 
   n 0-3   R 6  is (a) hydrogen;
 (b) hydroxy; 
 (d) 1-4C-alkoxy optionally substituted independently one or more times with
 (d1) OH, 
 (d2) —O-(1-4C-alkyl) 
 (d3) C(O)OR 9 , 
 (d4) C(O)NR 10 R 11 , 
 (d5) NR 10 R 11 , 
 (d6) —S-(1-4C-alkyl), 
 (d7) —S(O)-(1-4C-alkyl), 
 (d8) —SO 2 -(1-4C-alkyl) 
 (d9) SO 2 NR 10 R 11 , 
 (d10) heterocyclyl, which is optionally substituted with C(O)OR 9 , or oxo (═O), 
 (d11) heteroaryl, which is optionally substituted independently one or more times with cyano, 1-4C-alkyl, 1-4C-haloalkyl, 1-4C-haloalkoxy, C(O)OR 9 , C(O)NR 10 R 11 , (1-4C-alkylen)-O-(1-4C-alkyl), 
 
 (e) SO 2 NR 10 R 11 , 
 (f) 3-7C-cycloalkoxy, 
 (g) 1-6C-haloalkoxy, 
 (h) COOR 9 , 
 (i) —C(O)NR 10 R 11 , 
 (j) —O-heteroaryl opt. subst. with CN 
   
       
         
           
           
               
               
           
         
       
       whereby the * is the point of attachment,
 (l) —O-(2-4C-alkylen)-O-(1-4C-alkyl) which is optionally substituted with hydroxy, NH(CO)OR 9 , 
 R 7  is
 (a) hydrogen, 
 (b) (1-4C-alkyl)-heteroaryl 
 (c) 1-4C-haloalkyl, 
 (d) 1-4C-hydroxyalkyl, 
 
 
       
         
           
           
               
               
           
         
       
       whereby * is the point of attachment,
   (f) —C(O)-(1-4C-alkyl)   (g) —C(O)-(1-4C-alkylen)-O-(1-4C-alkyl)   (h) —C(O)-(1-4C-alkylen)-O-(2-4C-alkylen)-O-(1-4C-alkyl)   (i) —C(O)-heterocyclyl,   (j) benzyl whereby the phenyl ring is opt. subst with 1-5 substituents independently selected from the group consisting of
 hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-haloalkoxy, cyano, 
 C(O)OR 9 , 
   (k) heteroaryl   or   optionally, R 6  and R 7  together with the nitrogen atom to which R 7  is attached form a 6-membered ring which may contain one further heteroatom selected from the group consisting of O, S, N,
 and which is optionally substituted by (1-4C-alkyl)-OH, (1-4C-alkyl)-NR 10 R 11 , 
   
 R 8  is hydrogen, halogen, hydroxy, cyano, C(O)NR 10 R 11 , 1-4C-alkyl, 1-4C-hydroxyalkyl, 1-4C-haloalkyl, 1-4C-haloalkoxy, 
 m is 0-2, 
 R 9  is hydrogen, 1-4C-alkyl which optionally is substituted with hydroxy, 
 R 10 , R 11  are independently from each other hydrogen, 1-4C-alkyl, 1-4C-hydroxyalkyl, 1-4C-alkoxy, —C(O)-(1-4C-alkyl), or COOR 9  or
 together with the nitrogen atom to which they are attached form a 4-6-membered heterocyclic ring optionally containing one further heteroatom selected from the group consisting of O, S or N, which is optionally substituted with 1-2 fluorine atoms or COOR 9 , 
 
 or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer. 
 
     
     
         5 . The compound of formula (I) according to  claim 1 ,
 wherein,   R 1  is hydrogen,   R 2 /R 3  is independently hydrogen, fluorine, chlorine, bromine, cyano, hydroxy, CF 3 , —O—CH 3  or —O—CH 2 —CF 3 ,   R 4  is independently of each other hydrogen, fluorine, chlorine, bromine or iodine, cyano, NO 2 , hydroxy, —CH 3 , —C 3 H 7 , cyclopropyl, 1-propenyl, —C≡CH, —CF 3 , —CH 2 —OH, —CH 2 —CH 2 —OH, —C(CH 3 ) 2 —OH, —CH 2 —C(CH 3 ) 2 —OH, —C(CH 3 ) 2 —CH 2 —OH, —OCH 3 , —O—CH 2 —CH 3 , —OCF 3 , —OCF 2 H, —OCH 2 CF 3 , —O—(CH 2 )—O—C(O)—CH3, —C(O)CH 3 , —COOH, —C(O)OCH 3 , —C(O)OC 2 H 5 , —C(O)OC(CH 3 ) 3 , —CH 2 —COOH, —CH 2 —COOC 2 H 5 , —C(CH 3 ) 2 —COOC 2 H 5 , —C(O)NH 2 , —C(O)NH(CH 3 ), —C(O)N(CH 3 ) 2 , —C(O)NH—(CH 2 ) 2 —OH, —C(O)—(N-morpholinyl), —SO 2 —NH-cyclopropyl, —SO 2 —(N-morpholino), NH 2 , NH—C(O)(CH 3 ), 5-methyl-oxa-diazol-3-yl, N-pyrrolyl, N-pyrazolyl, —S—CF 3 , SF 5 ,
 whereby two of R 2 , R 3  (R 4 ) n , when positioned ortho to each other, form together —O—CH 2 —CH 2 —CH 2 —O—, —O—CH 2 —CH 2 —, —(CH 3 )C═CH—(C═O)—O—, 
 —CH 2 —(C═O)—O—, —(CH 2 ) 2 —(C═O)—NH—, which together with the two carbon atoms to which they are attached form a 5-, 6- or 7-membered ring, 
   n is 0, 1, 2, 3,   R 6  is hydrogen, hydroxy, cyano, —O-cyclopropyl, —OCH 3 , —OCF 3 , —OCF 2 H, —OCH 2 CF 3 , —O—(CH 2 ) 2 —OH, —O—(CH 2 ) 2 —NH 2 , —O(CH 2 ) 2 —N(CH 3 ) 2 , —O—(CH 2 ) 2 —O—CH 3 , —O—(CH 2 ) 2 —O—(CH 2 ) 2 —OH, —O—CH 2 —CH(OH)—CH 2 OH, —O—CH 2 —CH(OH)—CH 2 —NH—C(O)OC(CH 3 ) 3 , —O—CH 2 —COOH, —O—CH 2 —COOC 2 H 5 , C(O)NH 2 , —O—CH 2 —C(O)-(3-fluoro-N-azetidine), —O—CH 2 —C(O)-(3,3-difluoro-N-azetidine), —O—CH 2 —CH(OH)—CH 2 —N-piperidinyl, —O—(CH 2 ) 2 (morpholine-4-yl), —O—CH 2 -(morpholine-2-yl), —O—CH 2 -(morpholine-2-yl-4-tert-butoxycarboxylate), —O—CH 2 -(pyrrolidin-2-one-5-yl), —O—(CH 2 ) 2 —S—CH 3 , —O—(CH 2 ) 2 —SO—CH 3 , —O—(CH 2 ) 2 —SO 2 —CH 2 , —O—CH 2 —SO 2 NH 2 , —SO 2 —CH(CH 3 ) 2 ,   
       
         
           
           
               
               
           
         
       
       whereby * is the point of attachment,
   —O—(CH 2 ) 2 -tetrazolyl, —O—CH 2 -tetrazolyl, —O-pyridine-4-yl, —O-(3-cyano-pyridine-4-yl), or —O—CH 2 -(oxadiazole)-CH 2 —O—CH 3 ,   
 R 7  is hydrogen, methyl, difluoromethyl, hydroxyethyl, 
 
       
         
           
           
               
               
           
         
       
       whereby * is the point of attachment,
   —(CH 2 ) 2 -tetrazolyl, pyridine-4-yl, —C(O)-tetrahydropyran-4-yl, —C(O)—CH 2 —O—CH 3 , —C(O)—CH 3 , —C(O)CH 2 —O—(CH 2 ) 2 —O—CH 3 , C(O)OCH 2 —CH═CH 2 , or benzyl which is optionally substituted one or more times with fluorine, chlorine, bromine, cyano, methyl, difluoromethyl, methoxy, ethoxy, difluormethoxy, trifluoromethoxy, —O—CH 2 —CF 3 , —C(O)OCH 3 , or   optionally, R 6  and R 7  together with the nitrogen atom to which R 7  is attached form a 6-membered ring which may contain one further heteroatom selected from the group consisting of O, S, N and which in addition is optionally substituted by —CH 2 —OH or —CH 2 —NH—CHO   
 R 8  is hydrogen, fluorine, hydroxy, cyano, CH 3 , CF 3 , CH 2 —OH, OCH 3 , C(O)OH, C(O)OCH 3 , C(O)OC 2 H 5 , C(O)O(CH 2 ) 2 —OH, C(O)NH 2 , C(O)NHCH 3 , 
 m is 0, 1 or 2 
 or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer. 
 
     
     
         6 . Compounds of formula (I) according to  claim 1 , which is selected from the group consisting of:
 2-[1-(6-chloro-2-fluoro-3-methylbenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(6-chloro-2-fluoro-3-methoxybenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   5-methoxy-2-{1-[3-(5-methyl-1,2,4-oxadiazol-3-yl)benzyl]-1H-indazol-3-yl}-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(2-chloro-4,5-dimethylbenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   5-methoxy-2-{1-[4-(pentafluoro-λ 6 -sulfanyl)benzyl]-1H-indazol-3-yl}-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(2,6-difluoro-3-methoxybenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   N-(2,6-difluoro-3-methoxybenzyl)-2-[1-(2,6-difluoro-3-methoxybenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-{1-[(6-bromo-1,3-benzodioxol-5-yl)methyl]-1H-indazol-3-yl}-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   N-(4-ethoxy-2,6-difluorobenzyl)-2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)benzonitrile,   2-[1-(2-chloro-4-methoxybenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(2,6-difluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   N-(2,6-difluorobenzyl)-2-[1-(2,6-difluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   5-methoxy-N-(pyridin-4-yl)-2-(1-{3-[(trifluoromethyl)sulfanyl]benzyl}-1H-indazol-3-yl)pyrimidin-4-amine,   2-[1-(2,3-difluoro-4-methylbenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   N-(2,3-difluoro-4-methylbenzyl)-2-[1-(2,3-difluoro-4-methylbenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   5-methoxy-2-{1-[4-(1H-pyrazol-1-yl)benzyl]-1H-indazol-3-yl}-N-(pyridin-4-yl)pyrimidin-4-amine   2-[1-(2,6-dichlorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   N-(2,6-dichlorobenzyl)-2-[1-(2,6-dichlorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   5-methoxy-N-(pyridin-4-yl)-2-(1-{4-[(trifluoromethyl)sulfanyl]benzyl}-1H-indazol-3-yl)pyrimidin-4-amine,   2-[1-(2-chlorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   N-(2-chlorobenzyl)-2-[1-(2-chlorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   methyl 3-chloro-4-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)benzoate,   methyl 3-chloro-4-{[(2-{1-[2-chloro-4-(methoxycarbonyl)benzyl]-1H-indazol-3-yl}-5-methoxypyrimidin-4-yl)(pyridin-4-yl)amino]methyl}benzoate,   2-[1-(4-bromo-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(2-chloro-4-fluoro-3-methoxybenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(4-ethoxy-2,3-difluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   N-(4-ethoxy-2,3-difluorobenzyl)-2-[1-(4-ethoxy-2,3-difluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   5-methoxy-N-(pyridin-4-yl)-2-{1-[2,3,5,6-tetrafluoro-4-(2,2,2-trifluoroethoxy)benzyl]-1H-indazol-3-yl}pyrimidin-4-amine,   5-methoxy-N-(pyridin-4-yl)-N-[2,3,5,6-tetrafluoro-4-(2,2,2-trifluoroethoxy)benzyl]-2-{1-[2,3,5,6-tetrafluoro-4-(2,2,2-trifluoroethoxy)benzyl]-1H-indazol-3-yl}pyrimidin-4-amine,   methyl 2,4-dichloro-3-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)benzoate,   5-methoxy-N-(pyridin-4-yl)-2-[1-(2,4,6-trifluorobenzyl)-1H-indazol-3-yl]pyrimidin-4-amine,   5-methoxy-N-(pyridin-4-yl)-N-(2,4,6-trifluorobenzyl)-2-[1-(2,4,6-trifluorobenzyl)-1H-indazol-3-yl]pyrimidin-4-amine,   2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine   2-[1-(2,4-dichlorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(2-fluoro-4-iodobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(2-bromobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   N-(2-bromobenzyl)-2-[1-(2-bromobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   [3-fluoro-4-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)phenyl]acetic acid,   5-methoxy-N-(pyridin-4-yl)-2-[1-(2,3,5,6-tetrafluoro-4-methoxybenzyl)-1H-indazol-3-yl]pyrimidin-4-amine,   5-methoxy-2-[1-(4-propylbenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)pyrimidin-4-amine,   2-{1-[2,6-dichloro-4-(trifluoromethoxy)benzyl]-1H-indazol-3-yl}-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   N-[2,6-dichloro-4-(trifluoromethoxy)benzyl]-2-{1-[2,6-dichloro-4-(trifluoromethoxy)benzyl]-1H-indazol-3-yl}-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   7-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)-3,4-dihydroquinolin-2(1H)-one,   2-[1-(2-chloro-4-iodobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(3,5-dimethoxybenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-{1-[2-chloro-6-(trifluoromethyl)benzyl]-1H-indazol-3-yl}-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(2-chloro-5-fluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   7-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)-4-methyl-2H-chromen-2-one,   3-fluoro-4-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)benzonitrile,   4-{[{2-[1-(4-cyano-2-fluorobenzyl)-1H-indazol-3-yl]-5-methoxypyrimidin-4-yl}(pyridin-4-yl)amino]methyl}-3-fluorobenzonitrile,   2-{1-[2,6-dichloro-3-(trifluoromethyl)benzyl]-1H-indazol-3-yl}-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   ethyl [3-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)phenyl]acetate,   2-[1-(4-fluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   N-cyclopropyl-4-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)benzenesulfonamide,   6-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)-1-benzofuran-2(3H)-one,   2-{1-[4-(difluoromethoxy)-2,6-difluorobenzyl]-1H-indazol-3-yl}-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   tert-butyl 3-chloro-4-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)benzoate,   ethyl 2-[3-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)phenyl]-2-methylpropanoate,   4-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)benzonitrile,   5-methoxy-2-{1-[4-(morpholin-4-ylsulfonyl)benzyl]-1H-indazol-3-yl}-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(2,6-dichloro-3-nitrobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   3-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)benzonitrile,   N-[4-(difluoromethoxy)-2,6-difluorobenzyl]-2-{1-[4-(difluoromethoxy)-2,6-difluorobenzyl]-1H-indazol-3-yl}-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   5-methoxy-N-(pyridin-4-yl)-2-{1-[3-(1H-pyrrol-1-yl)benzyl]-1H-3-yl}pyrimidin-4-amine,   3,5-difluoro-4-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)benzonitrile   5-methoxy-2-{1-[2-methoxy-4-(trifluoromethyl)benzyl]-1H-indazol-3-yl}-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(2,6-difluoro-3-methylbenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(2-fluoro-6-methoxybenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   3,5-difluoro-4-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)benzamide,   2-[3,5-difluoro-4-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)phenoxy]ethyl acetate,   2-[1-(2,6-difluoro-4-propoxybenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(4-ethoxy-2-fluoro-6-methoxybenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-ol   2-[1-(4-methoxybenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-ol,   2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-ol,   2-[1-(4-fluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-ol,   {3-[({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)methyl]oxetan-3-yl}methanol,   {3-[({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)methyl]oxetan-3-yl}methanol,   (3-{[(2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-{[3-(hydroxymethyl)oxetan-3-yl]methoxy}pyrimidin-4-yl)(pyridin-4-yl)amino]methyl}oxetan-3-yl)methanol,   1-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)methanesulfonamide,   5-[2-(dimethylamino)ethoxy]-2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)-5-[2-(1H-tetrazol-5-yl)ethoxy]pyrimidin-4-amine,   2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)-5-[2-(1H-tetrazol-5-yl)ethoxy]-N-[2-(1H-tetrazol-5-yl)ethyl]pyrimidin-4-amine,   5-[2-(dimethylamino)ethoxy]-2-[1-(4-fluorobenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)-5-(1H-tetrazol-5-ylmethoxy)pyrimidin-4-amine,   5-[2-(dimethylamino)ethoxy]-2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)pyrimidin-4-amine,   1-({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)-3-(piperidin-1-yl)propan-2-ol,   2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-(2-methoxyethoxy)-N-(pyridin-4-yl)pyrimidin-4-amine,   tert-butyl 2-[({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)methyl]morpholine-4-carboxylate,   2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-[2-(morpholin-4-yl)ethoxy]-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-{[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]methoxy}-N-(pyridin-4-yl)pyrimidin-4-amine,   ethyl ({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)acetate,   1-(3,3-difluoroazetidin-1-yl)-2-({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)ethanone,   2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-[2-(methylsulfanyl)ethoxy]-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[2-({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)ethoxy]ethanol,   formic acid-(5S)-5-[({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)methyl]pyrrolidin-2-one (1:1),   (5R)-5-[({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)methyl]pyrrolidin-2-one,   tert-butyl {2-[2-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)ethoxy]ethyl}carbamate,   2-({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)-1-(3-fluoroazetidin-1-yl)ethanone,   (5S)-5-[({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)methyl]pyrrolidin-2-one,   tert-butyl [2-({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)ethyl]carbamate,   N-({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-8-(pyridin-4-yl)-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-7-yl}methyl)formamide,   2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(4-methoxybenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(4-cyclopropyl-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-(1-{2,6-difluoro-4-[(1E)-prop-1-en-1-yl]benzyl}-1H-indazol-3-yl)-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   1-[3,5-difluoro-4-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)phenyl]ethanone,   [2,4-dichloro-3-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)phenyl]methanol,   2-[3-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)phenyl]ethanol,   2-[3-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)phenyl]-2-methylpropan-1-ol,   [4-({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-methoxypyrimidin-4-yl}amino)pyridin-3-yl]methanol,   2-[3-chloro-4-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)phenyl]propan-2-ol,   1-[3-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)phenyl]-2-methylpropan-2-ol,   2-[2,4-dichloro-3-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)phenyl]propan-2-ol,   5-(difluoromethoxy)-2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)pyrimidin-4-amine,   5-(difluoromethoxy)-N-(difluoromethyl)-2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)pyrimidin-4-amine,   4-[(difluoromethyl)(pyridin-4-yl)amino]-2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]pyrimidin-5-ol,   2-[1-(4-methoxybenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)-5-(2,2,2-trifluoroethoxy)pyrimidin-4-amine,   2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)-5-(2,2,2-trifluoroethoxy)pyrimidin-4-amine,   3-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)propane-1,2-diol,   (2S)-3-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)propane-1,2-diol,   (2R)-3-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)propane-1,2-diol,   2-({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)ethanol,   2-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)ethanol,   ethyl 4-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-(2-hydroxyethoxy)pyrimidin-4-yl}amino)pyridine-3-carboxylate,   4-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-(2-hydroxyethoxy)pyrimidin-4-yl}amino)-N-methylpyridine-3-carboxamide,   4-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-(2-hydroxyethoxy)pyrimidin-4-yl}amino)pyridine-3-carboxamide,   2-hydroxyethyl 4-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-(2-hydroxyethoxy)pyrimidin-4-yl}amino)pyridine-3-carboxylate,   5-(cyclopropyloxy)-2-[1-(4-methoxybenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine hydrochloride (1:1),   (2S)-3-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)propane-1,2-diol hydrochloride (1:1),   2-({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)ethanol hydrochloride (1:1),   2-[1-(2,6-dichlorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine hydrochloride (1:1),   [2,4-dichloro-3-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)phenyl]methanol hydrochloride (1:1),   (2R)-3-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)propane-1,2-diol hydrochloride (1:1),   N-{2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]pyrimidin-4-yl}-N-(pyridin-4-yl)acetamide,   N-{2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]pyrimidin-4-yl}-2-methoxy-N-(pyridin-4-yl)acetamide,   N-{2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]pyrimidin-4-yl}-N-(pyridin-4-yl)tetrahydro-2H-pyran-4-carboxamide,   N-{2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]pyrimidin-4-yl}-2-(2-methoxyethoxy)-N-(pyridin-4-yl)acetamide,   2-[{2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]pyrimidin-4-yl}(pyridin-4-yl)amino]ethanol,   (3-{[{2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]pyrimidin-4-yl}(pyridin-4-yl)amino]methyl}oxetan-3-yl)methanol,   2-{1-[4-bromo-2-fluoro-6-(2,2,2-trifluoroethoxy)benzyl]-1H-indazol-3-yl}-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2-{1-[4-bromo-2,6-bis(2,2,2-trifluoroethoxy)benzyl]-1H-indazol-3-yl}-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   2,4-dichloro-3-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)benzoic acid,   ({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidin-5-yl}oxy)acetic acid,   2,4-dichloro-3-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)-N-methylbenzamide,   2,4-dichloro-3-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)benzamide,   2,4-dichloro-3-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)-N,N-dimethylbenzamide,   2,4-dichloro-N-(2-hydroxyethyl)-3-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)benzamide,   [2,4-dichloro-3-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)phenyl]morpholin-4-yl)methanone,   3,5-difluoro-4-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)-N-methylbenzamide,   2-[1-(4-ethynyl-2-fluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   {2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-8-(pyridin-4-yl)-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-7-yl}methanol,   2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-methyl-N-(pyridin-4-yl)pyrimidin-4-amine,   4-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-methoxypyrimidin-4-yl}amino)pyridine-3-carbonitrile,   2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N,N-di(pyridin-4-yl)pyrimidin-4-amine,   methyl 4-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-methoxypyrimidin-4-yl}amino)pyridine-3-carboxylate,   2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   4-({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-methoxypyrimidin-4-yl}amino)pyridine-3-carbonitrile,   2-[(3-{4-[(2,6-dimethylpyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]-5-ethoxy-3-fluorophenol,   4-({5-methoxy-2-[1-(4-methoxybenzyl)-1H-indazol-3-yl]pyrimidin-4-yl}amino)pyridin-2(1H)-one,   4-({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-methoxypyrimidin-4-yl}amino)pyridin-2(1H)-one,   4-({5-methoxy-2-[1-(4-propylbenzyl)-1H-indazol-3-yl]pyrimidin-4-yl}amino)nicotinonitrile,   4-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-methoxypyrimidin-4-yl}amino)pyridine-3-carboxamide,   4-({5-methoxy-2-[1-(4-propylbenzyl)-1H-indazol-3-yl]pyrimidin-4-yl}amino)pyridine-3-carboxamide,   4-({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-methoxypyrimidin-4-yl}amino)pyridine-3-carboxamide,   4-({2-[1-(2,6-difluoro-4-hydroxybenzyl)-1H-indazol-3-yl]-5-methoxypyrimidin-4-yl}amino)pyridine-3-carboxamide,   4-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-hydroxypyrimidin-4-yl}amino)pyridine-3-carbonitrile,   4-({4-[(3-cyanopyridin-4-yl)amino]-2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]pyrimidin-5-yl}oxy)pyridine-3-carbonitrile,   5-methoxy-2-[1-(4-methoxybenzyl)-1H-indazol-3-yl]-N-[3-(trifluoromethyl)pyridin-4-yl]pyrimidin-4-amine,   3-chloro-4-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)benzoic acid,   formic acid-3-chloro-4-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)-N-methylbenzamide (1:1),   3-chloro-4-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)-N-methylbenzamide,   4-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-hydroxypyrimidin-4-yl}amino)pyridine-3-carboxamide,   4-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-hydroxypyrimidin-4-yl}amino)pyridine-3-carboxylic acid,   ethyl 4-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-hydroxypyrimidin-4-yl}amino)pyridine-3-carboxylate,   2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidine-5-carbonitrile   2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-4-(pyridin-4-ylamino)pyrimidine-5-carboxamide,   4-({2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-(2-hydroxyethoxy)pyrimidin-4-yl}amino)pyridine-3-carboxylic acid hydrochloride (1:1),   N-(2-fluoropyridin-4-yl)-5-methoxy-2-[1-(4-methoxybenzyl)-1H-indazol-3-yl]pyrimidin-4-amine,   N-(2,6-difluoropyridin-4-yl)-5-methoxy-2-[1-(4-methoxybenzyl)-1H-indazol-3-yl]pyrimidin-4-amine,   N-(3-fluoropyridin-4-yl)-5-methoxy-2-[1-(4-methoxybenzyl)-1H-indazol-3-yl]pyrimidin-4-amine,   5-methoxy-2-[1-(4-methoxybenzyl)-1H-indazol-3-yl]-N-(2-methylpyridin-4-yl)pyrimidin-4-amine,   N-(difluoromethyl)-2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-[2-(methylsulfinyl)ethoxy]-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-[2-(methylsulfinyl)ethoxy]-N-(pyridin-4-yl)pyrimidin-4-amine (Enantiomer 1),   2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-[2-(methylsulfinyl)ethoxy]-N-(pyridin-4-yl)pyrimidin-4-amine (Enantiomer 2),   2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-[2-(methylsulfonyl)ethoxy]-N-(pyridin-4-yl)pyrimidin-4-amine,   5-(2-aminoethoxy)-2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-N-(pyridin-4-yl)pyrimidin-4-amine,   2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-(morpholin-2-ylmethoxy)-N-(pyridin-4-yl)pyrimidin-4-amine,   Preparation of ethyl 4-({2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-methoxypyrimidin-4-yl}amino)pyridine-3-carboxylate,   N-(3,5-difluoropyridin-4-yl)-2-[1-(4-ethoxy-2,6-difluorobenzyl)-1H-indazol-3-yl]-5-methoxypyrimidin-4-amine,   2-[1-(3-amino-2,6-dichlorobenzyl)-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   N-[2,4-dichloro-3-({3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl}methyl)phenyl]acetamide,   2-[1-(4-ethoxy-2,6-difluorobenzyl)-4-methyl-1H-indazol-3-yl]-5-methoxy-N-(pyridin-4-yl)pyrimidin-4-amine,   or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.   
     
     
         7 . Process for the manufacture of compounds of general formula (I) according to  claim 1 , wherein R 7  is hydrogen as reflected in formula (Ia), characterized in that a compound of formula (1-4) 
       
         
           
           
               
               
           
         
         whereby R 1 , R 2 , R 3 , R 4 , R 6  and n have the meaning according to  claim 1 , 
       
       is reacted with a compound of formula (C) 
       
         
           
           
               
               
           
         
         whereby R 8  and m have the meaning according to  claim 1 , and X′ represents F, Cl, Br, I, boronic acid or a boronic acid ester 
       
       in the presence of a suitable base, and a suitable palladium catalyst, optionally in the presence of a suitable ligand, 
       forming a compound of formula (Ia) 
       
         
           
           
               
               
           
         
       
       which is optionally subsequently deprotected to form a compound of general formula (I) wherein R 7  is hydrogen and R 1 , R 2 , R 3 , R 4 , R 6 , R 8  and n and m have the meaning as defined in  claim 1 . 
     
     
         8 . Process for the manufacture of compounds of general formula (I) according to  claim 1 , wherein
 a compound of formula (Ib)   
       
         
           
           
               
               
           
         
         whereby R 1 , R 2 , R 3 , R 6 , R 7 , R 8  and m have the meaning according to  claim 1  and R′ is 1-6C-alkyl or benzyl, 
         is treated with a suitable acid system to cleave the benzylic group in order to obtain a compound of formula 1-5 
       
       
         
           
           
               
               
           
         
         followed by reacting the compound of formula 1-5 with a compound of general formula (B), 
       
       
         
           
           
               
               
           
         
         
           wherein R 2 , R 3 , R 4  and n have the meaning according to  claim 1  and 
           X represents a leaving group, 
         
         in a suitable solvent system, in the presence of a suitable base, in a temperature range from room temperature to the boiling point of the respective solvent, to furnish compounds of general formula (I). 
       
     
     
         9 . An intermediate compound of general formula (1-5) according to  claim 7 , 
       
         
           
           
               
               
           
         
         whereby R 1 , R 6 , R 7 , R 8  and m have the meaning according to  claim 1 . 
       
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . A method for the treatment or prophylaxis of a hyperproliferative disease or disorder responsive to induction of apoptosis comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of general formula (I) according to according to  claim 1 , or an N-oxide, a pharmaceutically acceptable salt, a tautomer or a stereoisomer of said compound, or a pharmaceutically acceptable salt of said N-oxide, tautomer or stereoisomer. 
     
     
         13 . The method according to  claim 12 , whereby the hyperproliferative disease or disorder responsive to induction of apoptosis is a haemotological tumour, solid tumour or metastases thereof. 
     
     
         14 . The method according to  claim 12 , whereby the hyperproliferative disease or disorder responsive to induction of apoptosis is a tumour selected from cervical-, breast-, non-small cell lung-, prostate-, colon- and melanoma tumours or metastases thereof. 
     
     
         15 . A pharmaceutical composition comprising at least one compound of general formula (I) according to  claim 1 , together with at least one pharmaceutically acceptable auxiliary. 
     
     
         16 . (canceled) 
     
     
         17 . A combination comprising one or more first active ingredients selected from compounds of general formula (I) according to  claim 1 , and one or more second active ingredients selected from chemotherapeutic anti-cancer agents and target-specific anti-cancer agents.